Artuela Çaku

Artuela Çaku


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2014 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
AÇArtuela Çaku
Artuela Çaku
DPDavid Pellerin
David Pellerin
PBPaméla Bouvier
Paméla Bouvier
EREmilie Riou
Emilie Riou
FCFrancois Corbin
Francois Corbin

24 March 2016 in Biomarkers
Verified
Journal Article
Closed access
PDF file
DPDavid Pellerin
David Pellerin
AÇArtuela Çaku
Artuela Çaku
MFMathieu Fradet
Mathieu Fradet
PBPaméla Bouvier
Paméla Bouvier
JDJean Dubé
Jean Dubé
FCFrançois Corbin
François Corbin
Aim: To establish whether platelets from fragile X syndrome (FXS) individuals recapitulate FXS mouse neurons’ defects in ERK and Akt pathways, and to evaluate the effect of lovastatin on these pathways. Methods: ERK and Akt phosphorylation (pERK, pAkt) statuses were assessed with quantitative Western blotting before and after a 12-week lovastatin trial. Results: Levels of pERK and pAkt were increased in FXS platelets, and lovastatin specifically normalized ERK activity. Changes in ERK phosphorylation were correlated with clinical response to lovastatin. Conclusions: Platelets’ signaling pathways provide biomarkers that can be used as treatment outcome measures in FXS clinical trials.

23 March 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AÇArtuela Çaku
Artuela Çaku
NSNabil G. Seidah
Nabil G. Seidah
ALAudrey Lortie
Audrey Lortie
NGNancy Gagné
Nancy Gagné
PPPatrice Perron
Patrice Perron
FCFrancois Corbin
Francois Corbin
Fragile X Syndrome (FXS) is the main genetic cause of autism and intellectual deficiency resulting the absence of the Fragile X Mental Retardation Protein (FMRP). Clinical picture is characterized by cognitive impairment associated with a broad spectrum of psychiatric comorbidities including autism spectrum disorders and attention-deficit/hyperactivity disorders. Some of these disorders have been associated with lipid abnormalities and lower cholesterol levels. Since lipids are important for neuronal development, we aim to investigate the lipid profile of French Canadian-FXS individuals and to identify the altered components of cholesterol metabolism as well as their association with clinical profile. Anthropometric data were collected from 25 FXS individuals and 26 controls. Lipid assessment included: total cholesterol (TC), triglycerides, LDL, HDL, ApoB, ApoA1, PCSK9, Lp(a) and lipoprotein electrophoresis. Aberrant and adaptive behaviour of affected individuals was respectively assessed by the ABC-C and ABAS questionnaires. FXS participants had a higher body mass index as compared to controls while 38% of them had TC<10th percentile. Lower levels of LDL, HDL and apoA1 were observed in FXS group as compared to controls. However, PCSK9 levels did not differ between the two groups. As expected, PCSK9 levels correlated with total cholesterol (rs = 0.61, p = 0.001) and LDL (rs = 0.46, p = 0.014) in the control group, while no association was present in the FXS group. An inverse relationship was observed between total cholesterol and aberrant behaviour as determined by ABC-C total score. Our results showed the presence of hypocholesterolemia in French Canadian-FXS population, a condition that seems to influence their clinical phenotype. We identified for the first time a potential underlying alteration of PCSK9 function in FXS that could result from the absence of FMRP. Further investigations are warranted to better understand the association between cholesterol metabolism, PCSK9, FMRP and clinical profile.

6 August 2019 in Autism Research
Verified
Journal Article
Closed access
SBSérine Benachenhou
Sérine Benachenhou
AEAntoine Etcheverry
Antoine Etcheverry
LGLuc Galarneau
Luc Galarneau
JDJean Dubé
Jean Dubé
AÇArtuela Çaku
Artuela Çaku

28 September 2021 in Metabolites
Verified
Journal Article
Open access
PDF file
MBMaegan E. Boutot
Maegan E. Boutot
BWBrian W. Whitcomb
Brian W. Whitcomb
NANadia Abdelouahab
Nadia Abdelouahab
ABAndrea Baccarelli
Andrea Baccarelli
ABAmélie Boivin
Amélie Boivin
ASAlexander Suvorov
Alexander Suvorov
Animal studies have shown that developmental exposures to polybrominated diphenyl ethers (PBDE) permanently affect blood/liver balance of lipids. No human study has evaluated associations between in utero exposures to persistent organic pollutants (POPs) and later life lipid metabolism. In this pilot, maternal plasma levels of PBDEs (BDE-47, BDE-99, BDE-100, and BDE-153) and polychlorinated biphenyls (PCB-138, PCB-153, and PCB-180) were determined at delivery in participants of GESTation and Environment (GESTE) cohort. Total cholesterol (TCh), triglycerides (TG), low- and high-density lipoproteins (LDL-C and HDL-C), total lipids (TL), and PBDEs were determined in serum of 147 children at ages 6–7. General linear regression was used to estimate the relationship between maternal POPs and child lipid levels with adjustment for potential confounders, and adjustment for childhood POPs. In utero BDE-99 was associated with lower childhood levels of TG (p = 0.003), and non-significantly with HDL-C (p = 0.06) and TL (p = 0.07). Maternal PCB-138 was associated with lower childhood levels of TG (p = 0.04), LDL-C (p = 0.04), and TL (p = 0.02). Our data indicate that in utero exposures to POPs may be associated with long lasting decrease in circulating lipids in children, suggesting increased lipid accumulation in the liver, a mechanism involved in NAFLD development, consistent with previously reported animal data.

16 September 2023
Verified
Book Chapter
Closed access
SBSérine Benachenhou
Sérine Benachenhou
ALAsma Laroui
Asma Laroui
ODOlivier Dionne
Olivier Dionne
DRDaniela Rojas
Daniela Rojas
ATAmanda Toupin
Amanda Toupin
AÇArtuela Çaku
Artuela Çaku